What patents cover dolutegravir (and why there are multiple)
Dolutegravir is sold as a branded medicine (for example, Tivicay). Like many HIV drugs, it has multiple patent families covering different aspects of the product, such as the underlying compound, specific formulations, manufacturing processes, and sometimes medical-use claims. That is why you often see more than one patent number and several dates tied to different jurisdictions rather than a single “dolutegravir patent” expiration date.
When does the dolutegravir patent expire (by country)
Patent expiry depends on where the patent is filed, when the patent application priority dates were filed, and whether patents have been extended via local mechanisms (such as supplementary protection certificates in some jurisdictions). Without a specific country (US, EU, UK, Canada, India, etc.) and a specific patent/publication number, there is no single reliable expiration date you can apply globally.
How patent expiry affects generic and biosimilar competition
When relevant patents expire (or are invalidated or designed around), manufacturers can typically pursue generic versions, but they still must meet regulatory requirements for quality, bioequivalence, and labeling. Even after patent expiry, “evergreening” strategies (for example, new formulation patents) can delay some competition in certain markets because they may still block specific product presentations.
Can generic dolutegravir enter before the main patent ends?
Yes, sometimes. Entry can occur if:
- a company can launch a product that does not infringe the still-active patents (design-around), or
- courts narrow or invalidate claims, or
- a regulatory pathway is available that allows approval while infringement disputes are handled separately (jurisdiction-dependent).
The practical result is that generic availability timing can differ from the literal “last patent” date.
What happens during patent litigation (common for HIV small molecules)
Dolutegravir has historically attracted generic challengers in multiple countries, which can lead to:
- lawsuits alleging infringement by the brand,
- arguments that specific claims are invalid (for example, for lack of novelty or obviousness), and
- settlement agreements that can include agreed launch dates.
These disputes can change when competitors actually start selling, even if patents remain formally in force.
Which “dolutegravir patent” details matter most for investors and competitors
If you’re trying to track whether generics can enter, the most important facts are:
- the country (and sometimes the specific jurisdiction within it),
- the patent number or publication number,
- the priority date and the current term/expected expiry date,
- whether there are formulation or process patents still active, and
- any court injunctions or settlements affecting launch timing.
What you can share to get a precise answer
If you tell me the country (or region) and, if you have it, the patent number or brand name in that market (for example Tivicay), I can map that specific “dolutegravir patent” to its likely expiry and what it means for generic entry in that jurisdiction.
Sources
I’m missing the “provided information” needed to cite specific dolutegravir patent documents or expiry dates. If you share the country/region and the patent/publication number (or a link to the patent record you mean), I can produce a cited, accurate answer.